Immune Modulation in Heart Failure: the Promise of Novel Biologics

Current Treatment Options in Cardiovascular Medicine

Volumn 20, Issue 3, 2018, Pages

  Alvarez, Paulino ^a   Briasoulis, Alexandros ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Heart failure; Immunomodulation; Inflammation

Indexed keywords

APTAMER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL PRODUCT; CHEMOKINE; HEART ANTIBODY; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLAMMASOME; INTERLEUKIN 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL PRACTICE; HEART FAILURE; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 85044265165     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-018-0617-z     Document Type: Review

References (80)

1. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008;125(2):240–5. https://doi.org/10.1016/j.ijcard.2007.11.103.
2. Kitai T, Kirsop J, Tang WH. Exploring the microbiome in heart failure. Curr Heart Fail Rep. 2016;13(2):103–9. https://doi.org/10.1007/s11897-016-0285-9.
3. Sager HB, Kessler T, Schunkert H. Monocytes and macrophages in cardiac injury and repair. J Thorac Dis. 2017;9(Suppl 1):S30–5. https://doi.org/10.21037/jtd.2016.11.17.
4. Tracchi I, Ghigliotti G, Mura M, Garibaldi S, Spallarossa P, Barisione C, et al. Increased neutrophil lifespan in patients with congestive heart failure. Eur J Heart Fail. 2009;11(4):378–85. https://doi.org/10.1093/eurjhf/hfp031.
5. Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. 2011;89(1):12–9. https://doi.org/10.1093/cvr/cvq272.
6. Sugi Y, Yasukawa H, Kai H, Fukui D, Futamata N, Mawatari K, et al. Reduction and activation of circulating dendritic cells in patients with decompensated heart failure. Int J Cardiol. 2011;147(2):258–64. https://doi.org/10.1016/j.ijcard.2009.09.524.
7. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martínez-Maza O, Gage JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol. 2004;93(8):1007–11. https://doi.org/10.1016/j.amjcard.2003.12.054.
8. Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, et al. Serum complement activation in congestive heart failure. Am Heart J. 2001;141(4):684–90. https://doi.org/10.1067/mhj.2001.113758.
9. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–41. https://doi.org/10.1056/NEJM199007263230405.
10. Naftali-Shani, N., Levin-Kotler L.P., Palevski D., Amit U., Kain D., Landa N., Hochhauser E., Leor J., Left ventricular dysfunction switches mesenchymal stromal cells toward an inflammatory phenotype and impairs their reparative properties via toll-like receptor-4clinical perspective. Circulation, 2017. 135(23): p. 2271–2287, https://doi.org/10.1161/CIRCULATIONAHA.116.023527.
11. Timmers L, Sluijter JPG, van Keulen JK, Hoefer IE, Nederhoff MGJ, Goumans MJ, et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102(2):257–64. https://doi.org/10.1161/CIRCRESAHA.107.158220.
12. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rudiger M, et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res. 2008;78(1):26–35. https://doi.org/10.1093/cvr/cvn011.
13. Dhondup Y, Sjaastad I, Scott H, Sandanger Ø, Zhang L, Haugstad SB, et al. Sustained toll-like receptor 9 activation promotes systemic and cardiac inflammation, and aggravates diastolic heart failure in SERCA2a KO mice. PLoS One. 2015;10(10):e0139715. https://doi.org/10.1371/journal.pone.0139715.
14. Van Tassell BW, Raleigh JM, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12(1):33–41. https://doi.org/10.1007/s11897-014-0231-7.
15. deFilippi CR, Christenson RH. Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. JACC Heart Fail. 2015;3(3):253–6. https://doi.org/10.1016/j.jchf.2014.12.009.
16. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57–70. https://doi.org/10.1016/j.cca.2014.09.021.
17. Damas JK, et al. CXC-chemokines, a new group of cytokines in congestive heart failure—possible role of platelets and monocytes. Cardiovasc Res. 2000;45(2):428–36. https://doi.org/10.1016/S0008-6363(99)00262-X.
18. Waehre A, Vistnes M, Sjaastad I, Nygård S, Husberg C, Lunde IG, et al. Chemokines regulate small leucine-rich proteoglycans in the extracellular matrix of the pressure-overloaded right ventricle. J Appl Physiol (1985). 2012;112(8):1372–82. https://doi.org/10.1152/japplphysiol.01350.2011.
19. Matsubara J et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc, 2014. 3(4).
20. Cordero-Reyes AM, Youker KA, Torre-Amione G. The role of B-cells in heart failure. Methodist Debakey Cardiovasc J. 2013;9(1):15–9. https://doi.org/10.14797/mdcj-9-1-15.
21. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res. 2012;110(1):145–58. https://doi.org/10.1161/CIRCRESAHA.111.243360.
22. Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C, et al. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129(21):2111–24. https://doi.org/10.1161/CIRCULATIONAHA.113.007101.
23. Tang H, Zhong Y, Zhu Y, Zhao F, Cui X, Wang Z. Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy. Heart. 2010;96(10):765–71. https://doi.org/10.1136/hrt.2009.184945.
24. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116(7):1254–68. https://doi.org/10.1161/CIRCRESAHA.116.302317.
25. Zhu ZF, Tang TT, Dong WY, Li YY, Xia N, Zhang WC, et al. Defective circulating CD4+LAP+ regulatory T cells in patients with dilated cardiomyopathy. J Leukoc Biol. 2015;97(4):797–805. https://doi.org/10.1189/jlb.5A1014-469RR.
26. Altara R, et al. The CXCL10/CXCR3 Axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart. J Immunol Res. 2016;2016:4396368.
27. Janicki JS, Brower GL, Levick SP. The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling. Methods in molecular biology (Clifton, NJ). 2015;1220:121–39. https://doi.org/10.1007/978-1-4939-1568-2_8.
28. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 2000;101(21):2518–25. https://doi.org/10.1161/01.CIR.101.21.2518.
29. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103(8):1044–7. https://doi.org/10.1161/01.CIR.103.8.1044.
30. Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res. 2013;113(6):777–91. https://doi.org/10.1161/CIRCRESAHA.113.301413.
31. Nagarajan V, Hernandez AV, Cauthen CA, Starling RC, Tang WHW. Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. Am Heart J. 2017;183:35–9. https://doi.org/10.1016/j.ahj.2016.09.008.
32. Murphy KM, Rosenthal JL. Progress in the presence of failure: updates in chronic systolic heart failure management. Curr Treat Options Cardiovasc Med. 2017;19(7):50. https://doi.org/10.1007/s11936-017-0552-4.
33. Iborra-Egea O, Gálvez-Montón C, Roura S, Perea-Gil I, Prat-Vidal C, Soler-Botija C, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Systems Biology and Applications. 2017;3(1):12. https://doi.org/10.1038/s41540-017-0013-4.
34. Ma Y, Chilton RJ, Lindsey ML. Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension. 2012;59(5):908–10. https://doi.org/10.1161/HYPERTENSIONAHA.111.186494.
35. Medicine., U.S.N.L.o. ClinicalTrials.gov 2017 [cited 2017 11/22/2017]; Available from: https://clinicaltrials.gov/ct2/results?cond=Heart+Failure&term=immune&cntry1=&state1=&Search=Search&recrs=a&recrs=b.
36. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93(4):704–11. https://doi.org/10.1161/01.CIR.93.4.704.
37. Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112(22):3408–14. https://doi.org/10.1161/CIRCULATIONAHA.105.564971.
38. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized Etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594–602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2.
39. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2.
40. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101(4):890–8. https://doi.org/10.1172/JCI1112.
41. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–1. https://doi.org/10.1038/37022.
42. Torre-Amione G, Sestier F, Radovancevic B, Young J. Effects of a novel immunemodulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol. 2004;44(6):1181–6. https://doi.org/10.1016/j.jacc.2004.06.047.
43. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371(9608):228–36. https://doi.org/10.1016/S0140-6736(08)60134-8.
44. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104(3):271–80. https://doi.org/10.1172/JCI6709.
45. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJR, Yacoub MH. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;23(2):228–35. https://doi.org/10.1016/S1053-2498(03)00106-2.
46. Gao W, et al. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front Physiol. 2017;8:508.
47. Wang L, Li YL, Zhang CC, Cui W, Wang X, Xia Y, et al. Inhibition of toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2014;101(3):383–92. https://doi.org/10.1093/cvr/cvt258.
48. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D’Antoni ML, Debuque R, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118(3):400–9. https://doi.org/10.1161/CIRCRESAHA.115.307778.
49. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res. 2014;102(2):240–8. https://doi.org/10.1093/cvr/cvu025.
50. Nahrendorf M, Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res. 2013;112(12):1624–33. https://doi.org/10.1161/CIRCRESAHA.113.300890.
51. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–87. https://doi.org/10.1038/nm.3893.
52. Val-Blasco A, Piedras MJGM, Ruiz-Hurtado G, Suarez N, Prieto P, Gonzalez-Ramos S, et al. Role of NOD1 in heart failure progression via regulation of Ca(2+) handling. J Am Coll Cardiol. 2017;69(4):423–33. https://doi.org/10.1016/j.jacc.2016.10.073.
53. Damas JK, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure—modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol. 2001;38(1):187–93. https://doi.org/10.1016/S0735-1097(01)01335-3.
54. Jiang Y, Bai J, Tang L, Zhang P, Pu J. Anti-CCL21 antibody attenuates infarct size and improves cardiac remodeling after myocardial infarction. Cell Physiol Biochem. 2015;37(3):979–90. https://doi.org/10.1159/000430224.
55. Takahashi T. Toll-like receptors and myocardial contractile dysfunction. Cardiovasc Res. 2008;78(1):3–4. https://doi.org/10.1093/cvr/cvn044.
56. Knowlton AA. Paying for the tolls: the high cost of the innate immune system for the cardiac myocyte. In: Sattler S, Kennedy-Lydon T, editors. The immunology of cardiovascular homeostasis and pathology. Cham: Springer International Publishing; 2017. p. 17–34. https://doi.org/10.1007/978-3-319-57613-8_2.
57. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292(1):H503–9. https://doi.org/10.1152/ajpheart.00642.2006.
58. Topkara VK, Chambers KT, Yang KC, Tzeng HP, Evans S, Weinheimer C, et al. Functional significance of the discordance between transcriptional profile and left ventricular structure/function during reverse remodeling. JCI Insight. 2016;1(4):e86038. https://doi.org/10.1172/jci.insight.86038.
59. Wang J-W, Fontes MSC, Wang X, Chong SY, Kessler EL, Zhang YN, et al. Leukocytic toll-like receptor 2 deficiency preserves cardiac function and reduces fibrosis in sustained pressure overload. Sci Rep. 2017;7(1):9193. https://doi.org/10.1038/s41598-017-09451-3.
60. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108(23):2905–10. https://doi.org/10.1161/01.CIR.0000101921.93016.1C.
61. Sager HB, Dutta P, Dahlman JE, Hulsmans M, Courties G, Sun Y, et al. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med. 2016;8(342):342ra80. https://doi.org/10.1126/scitranslmed.aaf1435.
62. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ Res. 2016;119(7):853–64. https://doi.org/10.1161/CIRCRESAHA.116.309001.
63. Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchanskiy A, Garrett MR, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol. 2017;112(3):33. https://doi.org/10.1007/s00395-017-0622-5.
64. Hasan AS, Luo L, Yan C, Zhang TX, Urata Y, Goto S, et al. Cardiosphere-derived cells facilitate heart repair by modulating M1/M2 macrophage polarization and neutrophil recruitment. PLoS One. 2016;11(10):e0165255. https://doi.org/10.1371/journal.pone.0165255.
65. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D. Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res. 2009;82(2):229–39. https://doi.org/10.1093/cvr/cvp001.
66. Li J, Jubair S, Levick SP, Janicki JS. The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metabolic & Endocrine. 2016;10(Supplement C):16–23. https://doi.org/10.1016/j.ijcme.2015.11.003.
67. Yoshikawa T, Baba A, Akaishi M, Wakabayashi Y, Monkawa T, Kitakaze M, et al. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column—a prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. J Clin Apher. 2016;31(6):535–44. https://doi.org/10.1002/jca.21446.
68. Haberland A, Holtzhauer M, Schlichtiger A, Bartel S, Schimke I, Müller J, et al. Aptamer BC 007—a broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. 2016;789:37–45. https://doi.org/10.1016/j.ejphar.2016.06.061.
69. Stephenson E, Savvatis K, Mohiddin SA, Marelli-Berg FM. T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation. Br J Pharmacol. 2017;174(22):3914–25. https://doi.org/10.1111/bph.13613.
70. Youker KA, Assad-Kottner C, Cordero-Reyes AM, Trevino AR, Flores-Arredondo JH, Barrios R, et al. High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. Eur Heart J. 2014;35(16):1061–8. https://doi.org/10.1093/eurheartj/eht506.
71. Nagatomo Y, McNamara DM, Alexis JD, Cooper LT, Dec GW, Pauly DF, et al. Myocardial recovery in patients with systolic heart failure and autoantibodies against beta1-adrenergic receptors. J Am Coll Cardiol. 2017;69(8):968–77. https://doi.org/10.1016/j.jacc.2016.11.067.
72. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101(4):385–91. https://doi.org/10.1161/01.CIR.101.4.385.
73. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in beta(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail. 2012;14(12):1374–88. https://doi.org/10.1093/eurjhf/hfs123.
74. Ohlow MA, Brunelli M, Schreiber M, Lauer B. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: results from the observational prospective Bad Berka Registry. J Cardiol. 2017;69(2):409–16. https://doi.org/10.1016/j.jjcc.2016.07.014.
75. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. 2015;8(4):776–87. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002225.
76. Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10(3):e003688. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003688.
77. Okamoto N, Noma T, Ishihara Y, Miyauchi Y, Takabatake W, Oomizu S, et al. Prognostic value of circulating regulatory T cells for worsening heart failure in heart failure patients with reduced ejection fraction. Int Heart J. 2014;55(3):271–7. https://doi.org/10.1536/ihj.13-343.
78. Wang H, Hou L, Kwak D, Fassett J, Xu X, Chen A, et al. Increasing regulatory T cells with Interleukin-2 and Interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression. Hypertension. 2016;68(1):114–22. https://doi.org/10.1161/HYPERTENSIONAHA.116.07084.
79. Kallikourdis M, Martini E, Carullo P, Sardi C, Roselli G, Greco CM, et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun. 2017;8:14680. https://doi.org/10.1038/ncomms14680.
80. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015;116(8):1413–30. https://doi.org/10.1161/CIRCRESAHA.116.303614.